Compare Amylx Pharmaceuticals Inc (AMLX) vs Barrick Gold Corp (B) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Barrick Gold Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.65 (market cap $1.98B), while Barrick Gold Corp trades at $36.3 (market cap $61.25B). The key difference: Barrick Gold Corp is far larger — about 30.9× Amylx Pharmaceuticals Inc's market cap, and Barrick Gold Corp pays a 1.91% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | B | |
|---|---|---|
Market Cap | $1.98B | $61.25B |
Sector | Health | Basic Materials |
52-Week High | $18.70 | $52.97 |
52-Week Low | $7.64 | $20.73 |
Enterprise Value | $1.70B | $58.85B |
Dividend Yield | — | 1.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Barrick Mining (B) trades at $36.68, down 0.41% on the day, with a bearish technical signal but strong fundamentals. The company reported robust 2025 results with revenue of $16.96B and net income of $4.99B, beating earnings estimates in recent quarters. Analyst consensus is strongly bullish with a $51.80 price target, though technical indicators show near-term weakness with support at $36.
The stock presents a value opportunity with a low P/E of 10.07 and strong cash flow growth, but faces headwinds from gold price volatility and bearish momentum. Upside potential exists if Q2 2026 earnings meet or exceed expectations, while risks include commodity price swings and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →
